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2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)
as a Potent and Persistent Thyroxine
Agonist: A Mechanistic Model for Toxicity
Based on Molecular Reactivity
by J. D. McKinney,* J. Fawkes,* S. Jordan,* K. Chae,*
S. Oatley,t R. E. Coleman,* and W. Brinert
TCDD and thyroxine have common molecular reactivity properties which enable them to present a planar
face and lateral halogens in interactions with proteins. These molecular properties are consistent with
the structure-toxicity relationship for TCDD and related compounds. Biological evidence is discussed
including preliminary studies on the effects ofTCDD exposure on tadpole growth and development which
is consistent with the possible thyroxine-like activity of TCDD. The work suggests the possibility that
toxicity is at least in part the expression of potent and persistent thyroid hormone activity (responses
induced by TCDD which qualitatively correspond to those mediated by thyroid hormones). A mechanism
for toxicity is proposed which involves receptor proteins; the planar aromatic system controls binding to
cytosolic proteins and halogen substituents regulate binding to nuclear proteins. This simple model based
on molecular reactivity sheds light on the diversified effects ofTCDD and related compound toxicity and
on certain thyroid hormone action. The model also permits predictions to be made with regard to the
toxicity and thyroid hormone activity of untested compounds. In addition, the model suggests a general
mechanism for hormone action based on metabolically regulated differential and cooperative protein
receptor binding events in cellular compartments which can explain agonism, antagonism andpotentiation
within the framework of receptor occupancy theory.
Introduction
The halogenated aromatic hydrocarbons constitute a
broad class of environmentally important compounds
with varying structure and toxicity (1). 2,3,7,8-Tetrach-
lorodibenzo-p-dioxin (dioxin or TCDD) the prototypical
structure (Fig. 1) is the most toxic compound of this
type and is also a potent inducer of cytochrome P-448-
mediated mixed-function oxidase enzyme systems. The
mechanism oftoxicity ofthese compounds has been un-
der intense study in a number of laboratories through-
outtheworld. Thetoxicityandinduction responseshave
both been proposed to involve initial binding ofthe hy-
drocarbon to the same cytosolic (Ah or dioxin receptor)
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receptor, but the subsequent events are not completely
understood (2). We recently provided evidence in the
form of theoretical and experimental models that the
structure-toxicity (defined as the acute lethal toxicity
normally associated with TCDD) and the structure-in-
duction relationships are different. Binding to the in-
duction receptor appears to involve the aromatic rings
in a stacking type interaction while binding to the hy-
pothetical "toxic" receptor may involve polarizability
interactions with halogen substituents (3). To account
for the differences in the structure-activity relation-
ships, a cooperative receptor (requiring interaction of
TCDDwithtwoproteins withdifferentstructuralparts)
mechanism for toxicity was postulated. This work also
suggested that a more toxicologically relevant binding
protein should be sought because of the requirements
of planarity and halogenation for toxicity, as opposed
to induction.
The thyroid hormone-binding proteins are likely can-
didates as receptors for TCDD and related compounds
because oftheir specificities for binding the biologicallyMcKINNEY ET AL.
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FIGURE 1. TCDD and thyroid hormone structures.
relevant halogenated aromatic hydrocarbon hormones,
thyroxine (T4) and triiodothyronine (T3) (Fig. 1). Thy-
roxine-binding prealbumin (TBPA) is a major carrier
protein for T4 in blood and has been used by others as
a model for the interaction of thyroid hormones with
the nuclear thyroid hormone receptor (4). Using inter-
active computergraphics, themolecularinteractionsbe-
tween TCDD and TBPA were modeled. This work
succeeded inlinkingthe structure ofTCDD tothe struc-
ture ofT4. We were also able to demonstrate that TCDD
type structures could compete with T4 for binding to
TBPA (5). This nuclear receptor model for thyroxine
fulfills the requirements of the hypothetical "toxic" re-
ceptor since it requires halogenation in lateral positions
for effective binding. The structuralresemblance ofcer-
tain chlorinated aromatic hydrocarbons to the thyroid
hormones and the potential of these compounds to act
asthyroid hormone agonists or antagonists and produce
aberrant thyroid activity was first recognized over 15
years ago (6).
Thus a plausible mechanism for TCDD and related
compound toxicity could be associated with their ability
specifically to bind proteins and to function as potent
and persistent thyroxine agonists or antagonists. Con-
sistent with this suggestion is a range of clinical and
biochemical findings in TCDD treated animals that re-
semble both the hypo- and hyperthyroid disease states
(2,7). Serum T4 depletion has been a consistent finding
along with unchanged or slightly elevated triiodothy-
ronine (T3) levels (8,9), suggesting perhaps more direct
involvement of T4 specific binding proteins and recep-
tors. The long-range objectives of this work were to
identify common molecular reactivity properties for
TCDD and T4 consistent with the structure-toxicity
relationships; to propose a simple mechanistic model for
toxicitybased onmolecularstructure andreactivitythat
could explain the structure-toxicity results and is con-
sistent with major clinical and toxicological outcomes of
these and related compounds and has predictive value
for untested compounds, and to establish that TCDD is
a thyroxine agonist at the level oftissue receptors and
link the mechanism oftoxicity to the mechanism ofthy-
roid hormone action.
Experimental
Materials
The TCDD used in this work was synthesized at this
institute according to published procedures (10). Gas
chromatography-mass spectroscopy was used to deter-
mine purity which was >99%.
The '25I-thyroxine (-1250 ,uCi/,ug) used in this work
was obtained commercially (New England Nuclear
Corp). The radiochemical purity determined by the
manufacturer approximately one month prior to use by
an HPLC method was > 99%. Radiochromatography
performed in our laboratory 24 hrs prior to use, using
aTLC silicagelstripand adevelopingsolventcomposed
of hexane:2-methyl-2-butanol:methanol:NH40H (4N),
1:6:2:1, revealed a radiochemical purity > 97%.
The labeled hormone is shipped in 50% n-propanol
which is unsuitable for parenteral use in animals. Thus,
immediately before dosing (by gavage) the hydroalco-
holic solution of '25I-T4 was rapidly reduced in volume
by a nitrogen stream until the original volume of 2.5
mL had been reduced to 1.6 mL. This solution was
brought to 2.0 mL total volume by adding 0.4 mL of
sodium chloride solution, 0.9%, USP. Each animal re-
ceived 0.3 mL (80 ,uCi or 88 ng) of this solution.
Molecular Modeling
The model building shown in Figure 3 was carried
out in the computer graphics laboratory ofthe Depart-
mentofChemistry, University ofCalifornia, San Diego,
using a Silcon Graphics Iris system. The coordinates for
TCDD and T4 were those previouslyused (5) with some
small adjustments forthe torsion angles aboutthe ether
linkageoftheT4structure. Askewedconformation with
torsion angles +/4' = 800/00 was used which is well
within the acceptable range as indicated by energy cal-
culations (11) and crystallographic observations (12) on
a variety ofsimilar structures. The overall relationship
ofthe two molecules was modeled as suggested by our
previous work (5) with prealbumin where there is close
correspondence of the lateral chlorines in TCDD with
the lateral iodines and hydroxyl group in the phenolic
ring of T4. The superposition stereopair model shown
(Fig. 3)representstheleast-squaresfitontheimportant
atoms. Table 1 shows the atomic deviations for the im-
portant atoms in this fit.
Thyroxine Measurements
Serum: Rats/Guinea Pigs. Groups of five male
Sprague-Dawley CD rats (200-250 g, 6 weeks old) were
administered TCDD at 0, 12, 25, 37, or 50 ,ug/kg body
weight doses. Each animal was given TCDD in corn oil
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Table 1. Least-squares fit of TCDD and T4 structures.
TCDDa T4a Atomic deviations, A
C1-3 CH2 (side chain) 0.12
0-10 0 (ether) 0.86
0-5 I-5 2.89
Cl-7 0 (hydroxyl) 1.02
Cl-8 I-5' 0.81
C-i I-3 1.95
C-6 I-3' 1.81
aSee Fig. 1 for location of atoms.
(0.1 mL/kg body weight) by gavage and housed and
maintained according to standard procedures (10). Con-
trol animals were dosed similarly with corn oil alone.
Groups offive male Hartley strain guinea pigs (100-200
g, 3.5 weeks old) were similarly dosed with TCDD at
0, 0.5, 1.0, 1.5, or 2.0 ,ug/kg body weight. All animals
were held9daysbefore sacrificingwith C02 euthanasia.
Blood was taken by cardiac puncture after breathing
had stopped. Blood was allowed to clot, spun down, and
the serum transferred to another tube and spun again
before use.
Serum thyroxine measurements were made by using
a standard radioimmunoassay kit from commercial
sources (Tetra-Tab RIA, Nuclear-Medical Laborato-
ries, Irving, TX). In this procedure an acid reagent is
mixed with a serum sample to release the thyroxine
fromproteins. Thethyroxine isthen allowed to compete
with radiolabeled thyroxine for a limited number of
binding sites on highly specific antibody. Free and an-
tibody-bound fractions are then separated by addition
of an ammonium sulfate solution to precipitate the an-
tibody-bound fraction. Following centrifugation, super-
natant fluid is discarded and the radioactivity in the
precipitate is measured directly in a gamma scintillation
spectrometer. Results are determined by comparison
with a standard curve.
Tissue: Rat. Groups ofthree male Sprague-Daw-
ley CD rats (200-250 g, 6 weeks old) were administered
TCDD at 0 and 25 ,ug/kg body weight doses. Each an-
imal was given TCDD in corn oil by gavage (0.1 mL/kg
body weight) and housed and maintained according to
standard procedures (10). Control animals were dosed
with corn oil alone. All animals were held for 9 days
before receiving 0.3 mL of '25I-thyroxine solution by
gavage, equivalent to 80 ,uCi and 88 ng of the labeled
hormone. Immediately following this treatment, each
animal was anesthetized by using metofane, and whole
body radioactivity was determined (day 0) by using a
computer controlled gamma camera with a pin-hole col-
limator with careful and fixed positioning ofthe animal.
These measurements were again made on each animal
24 and 48 hr later (day 1 and day 2). After the day 2
measurements were made the animals were sacrificed
by euthanasia. Blood was taken by cardiac puncture
after breathing had stopped. Organs were surgically
removed and placed into tared vials for weighing and
gamma counting.
Tadpole Study
Materials. Tadpoles of Xenopus laevis were ob-
tained commercially from Nasco at stages 48 to 55 (Nasco
Flyer No. 649) in which total length ranged from 14 to
80 mm. They were allowed to reach room temperature
overnight then mixed with an equal volume ofchlorine-
free water (well water) at the same temperature. Ex-
perimental animals were visually sorted into sizes rang-
ing from 27 to 37 mm (stage 51), an interval when hind
leg development was approximately 1 to 2 mm. Mea-
surement parameters were obtained from serial pho-
tographs. Twenty tadpoles in 150 mL of water were
added to each aquarium. Frog brittle from Nasco, a
special food formulation for Xenopus tadpoles, was
blended for 1 min (2 gpowder/100 mL deionized water).
The suspension was maintained by successive drawing
and expellingin a 10 mL syringe, and 5 mL wasinjected
into the water (1 gal). Suspension volumes were further
adjusted as needed so that the water became clear within
24 hr. Fresh suspensions were prepared daily.
Aquarium water was changed at intervals not ex-
ceeding 8 days. To minimize animal injury, tadpoles
were removed by scooping rather than collecting in nets.
Before returning to a fresh water change, they were
photographed in a 7 x 7 x 3 in. transparent plastic
container (made of acrylic and glued together with
methylene chloride) on translucent background illumi-
nation. Since the camera was hand-held, a transparent
grid of10 squares/in, 7in. longwasincludedinthephoto
so that size corrections could be madebetween different
photographs. Tadpoles were identified as frogs when
both sets of legs were fully functional and the body
structure was that of a frog.
Aquarium Maintenance Because of the toxicity
of TCDD, 2.5 gal. glass-covered aquarium tanks were
placed into standard plastic rat cages to collect any ac-
cidentally spilled aquarium contents. Well water was
collected in 1-gallon, screw-cap glass jugs 1 or 2 days
before use. Just before use, 0.8 mL acetone was added
without mixing, followed with another 0.8 mL acetone
containing 4 ,ug, 2 ,ug, and 0.4 ,ug TCDD, respectively
(approximately 1.0, 0.5, and 0.1 ppb). Control water
contained 1.6 mL acetone only. Mixingwas byinversion
10 to 12 times. Before placing tadpoles in the tank, food
suspension was immediately added. Water was aerated
with an air pump by bubbling through an airstone dif-
fuser. Acetone (0.2 mL) was added daily directly over
the diffuser to maximize mixing and maintain solubility
of TCDD. Liquid crystal thermometers on the outside
of the jugs and aquaria were used to monitor water
temperature kept at 68 + 20F.
Logistics ofHandling Used TCDD Water and the
Cleaning ofAquarium Tanks. When tank water was
to be changed the animals were first removed and then
the aquaria were emptied through funnels into 4-L Er-
lenmeyer flasks. The solution was vacuum-filtered once
to remove particulate matter through a Whatman 15
cm No. 651 and CD/F microcrystalline glass filters con-
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Table 2. Whole body counts from TCDD-treated rats receiving 1251-thyroxine 9 days later.'
Control Treated
Time, days Animal Counts Animal Counts
Ob A 2540 X 4340
B 2940 Y 4140
C 3140 Z 3640
Mean (± SD) 2873 (±305.5) Mean (± SD) 4040 (±360.6)
1 A 1040 X 940
B 1040 Y 520
C 1040 Z 840
Mean (± SD) 1040 (±0) Mean (± SD) 767 (±219.4)
2 A 430 X 240
B 440 Y 120
C 510 Z 300
Mean (± SD) 460 (±43.6) Mean (± SD) 220 (±91.7)
'Obtained using gamma camera with a pen-hole collimator with careful and fixed positioning of the animals and background corrected.
bDay 0 is immediately following (-0.5 hr later) the "WI-thyroxine treatment.
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FIGURE 2. Thyroxine concentration in rat serum as a function of
TCDD dose (mean ± SD, N = 5).
tained in a Buchner funnel. Fresh filter papers were
again added plus a mixture ofactivated charcoal:Celite
(1:1 w/w) for final filtration. Filtrates were stored in 40-
L Nalgene screw-cap carboys to be later discarded.
Before refilling the aquaria, tank sides and bottom
were first wiped clean with moistened paper towels fol-
lowed with acetone soaked towels to remove residual
TCDD. To minimize chance infection from aeromonas
bacteria, cleansing powder was used to wipe sides and
bottom. Afterthorough tap waterrinsing, the tank was
towel dried. The paper products were bagged and
incinerated.
Statistical Methods
Linearregression analyses (13) were employed to de-
termine whether or not tadpole length, width or size
were age-related in dosed and control groups. Analysis
of variance procedures (14) were used to assess the
significance of dose and age-effects. Two-sided t-tests
(14) were used to make pairwise comparisons between
dosed and control groups. Probabilities of frog forma-
tion and rates of death were estimated by the product
limit procedure ofKaplan and Meier (15).
Results
Serum T4 levels were determined in rats following
single oral doses of12, 25, 37, and 50 ,ug/kgbodyweight
Table 3. Tissue counts from TCDD-treated rats receiving
"'I-thyroxine 9 days later and held for another 2 days.
Control Treated Control
Tissue (mean + SD)' (mean ± SD)' Treated
Liver 82,471 (±3414) 15,791 (±7146) 5.22
Blood 70,883 (± 7297)b 18,407 (±8837) 3.85
Spleen 20,002 (±2104) 5,333 (± 1880) 3.75
Kidney 70,277 (± 5872) 20,163 (±8219) 3.49
Adrenal 42,113 (±8880) 12,887 (± 5348) 3.27
Thymus 14,644 (±2546) 6,063 (±2451) 2.42
Thyroid 28,682,834 (±9,016,564) 18,572,556 (±6,158,614) 1.54
GI tract 86,308 (±39,541) 113,718 (± 42,717) 0.76
an= 3 unless specified otherwise.
bn= 2.
ofTCDD given 9 days earlier. The results ofthese mea-
surements are shown in Figure 2. T4 levels appeared
to be linearly depleted between 0 and 25 ,ug/kg doses
and remained fairly constant at about half the control
level at the higher more toxic doses. Extrapolation of
the linear phase to the dose for complete depletion of
serum T4 corresponds closely with the lethal dose of
TCDD in this rat species. A similar study in a much
moreTCDD sensitiveguineapigwithTCDD doselevels
between 0 and 2 ,g/kg body weight afforded serum T4
levels in control animals (2.78 ± 0.57 ,ug/dL, n = 5)
about one-third the level found in rats and T4 levels in
TCDD-treated animals consistently elevated by about
1 pig/dL (complete data not shown).
Studies ofTCDD-treated rats (25 jig/kgbodyweight)
given a tracer dose of 1251-T4 9 days later showed that
the TCDD-treated animals excreted T4 at about twice
the rate as controls (Table 2), and this is reflected in
depletion oftissue T4 as indicated in Table 3. This pat-
tern was reversed in the GI tract as expected, since
this tissue is involved in the elimination of T4
glucuronide.
In order to test the possibility that TCDD can func-
tion as a thyroid hormone agonist and interact directly
with tissue receptors, the effects of TCDD on tadpole
growth and development were studied. For reasons of
safety and convenience, the effects were measured
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Table 4. Average growth parameters ofXenopus laevis tadpoles as a function of age and TCDD concentration in water.
No.
Tb Fb
20 0
20 0
20 0
20 0
20 0
20 0
7 0
0 0
Age, days
8
8
8
8
16
16
16
16
20 0 23
18 1 23
0 0 23
0 0 23
19 0 30e
f f 30e
0 0 30
0 0 30
17 2
13 3
0 0
0 0
38
38
38
38
16 3 42
9 2 42
0 0 42
0 0 42
13 1 51
8 2 51
0 0 51
0 0 51
10 3 58
1 0 58
0 0 58
0 0 58
Length, in.
0.49 ± 0.06
0.55 ± 0.07*
0.43 ± 0.05*
0.36 ± 0.06*
0.47 ± 0.07
0.53 ± 0.08*
0.41 ± 0.06
0.52 ± 0.08
0.49 ± 0.08
0.53 ± 0.06
f
0.49 ± 0.07
0.45 ± 0.07
0.48 ± 0.06
0.43 ± 0.04
0.51 t 0.05
0.42 t 0.05*
0.50 t 0.07
Size parameterc
Width, in.
0.26 ± 0.04
0.26 ± 0.05
0.22 ± 0.05*
0.19 ± 0.05*
0.28 ± 0.04
0.28 ± 0.06
0.18 ± 0.03
0.28 ± 0.05
0.27 ± 0.04
0.27 ± 0.05
f
0.27 ± 0.04
0.24 ± 0.04
0.26 ± 0.05
0.24 ± 0.04
0.28 ± 0.05
0.23 ± 0.04
0.28 ± 0.07
5 3 66
1 0 66
0 0 66
0 0 66
0.45 ± 0.04 0.25 + 0.03 0.115 ± 0.019
aGroup: C = control; Lo = low dose (0.1 ppb); M = medium dose (0.5 ppb) H = high dose (1.0 ppb).
'T = tadpoles; F = frogs (total number of living animals).
CLength and width parameters ofeach tadpole were measured directly from photographs which were corrected from a grid (10 lines/inch) in-
cluded in the photo. Length measurements included the body but not the tail. Widths were measured at the widest pointjust behind the eyes.
Values are means ± SD (in inches).
S = size (length x width).
eTadpoles were transferred to TCDD-free water.
'Photo not available.
p < 0.05 relative to controls.
throughthe use ofserialphotgraphs. Tadpolesreceiving
medium doses (0.5 ppb) and high doses (1.0 ppb) of
TCDD showed significant dose-related decreases in
length from controls (p < 0.05) within 8 days after the
beginningoftheexperiment (Table4). Alltadpoles were
dead by day 16 and day 23, respectively, for the high
and medium dose levels. Even by day 16 the 0.5 ppb
dose level mortality was 65%. Similar results were ob-
tained in earlier studies (data not shown).
Tadpoles dosed at the lower level (0.1 ppb), on the
other hand, showed significantly greater growth than
the control by day 8 and 16 for length (p < 0.05). How-
ever, after day 16 growth values were less than the
controls but the difference was not significant until day
51 (p < 0.02 in length and size only). Tadpoles dosed at
the 0.1 ppb level were maintained in TCDD-free water
from day 30 to the end of the experiment to avoid the
possibility thatalltadpoles might diebeforebeingtrans-
formed to frogs.
Theresults oflinearregressionanalysisindicatedthat
Groupa
C
Lo
M
H
C
Lo
M
H
C
Lo
M
H
C
Lo
M
H
C
Lo
M
H
C
Lo
M
H
Sized
0.130 ± 0.030
0.147 ± 0.041
0.095 ± 0.028*
0.70 ± 0.18*
0.135 + 0.038
0.151 + 0.049
0.075 t 0.020*
0.154 t 0.039
0.130 t 0.040
0.145 t 0.035
f
0.135 t 0.037
0.112 t 0.030
0.128 t 0.038
0.106 t 0.024
0.144 -+ 0.041
0.098 ± 0.026*
0.146 ± 0.055
C
Lo
M
H
C
Lo
M
H
C
Lo
M
H
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for the controls there was no significant change in length,
width, or size over time (Table 5). In contrast, for the
low dose (0.1 ppb) groups, all three ofthese parameters
showed time-related decreases.
The number of tadpoles that eventually developed
Table 5. Estimated coefficients of linear regression of
tadpole growth over time.
Group Variablea Intercepts Slope p Valueb
Control Length 0.50 -0.00014 0.69
Width 0.27 -0.000019 0.94
Sizec 0.14 -0.000034 0.86
Low dose Length 0.57 -0.0031 0.0001
(0.1 ppb) Width 0.28 -0.00078 0.023
Sizec 0.16 -0.0012 0.0001
aUnits of measure: inches for length and width; (inch)2 for size.
bFor testing the hypothesis of zero slope, i.e., is tadpole growth
significantly affected over time.
CLength x width.
into frogs was identical (7) in dosed and control groups.
There were, however, differences between the two
groups. Not only did frogs appear earlier in the dosed
group as compared to the controls, but there was also
atendency for accelerated metamorphosis. Frogs in the
dosed group also showed evidence of muscle tremors
consistent with hyperactivity. By day 42 seven frogs
were formed in the dosed group but only three were
produced in the controls. At the end ofthe experiment
there were seven and four dead frogs in the dosed and
control groups, respectively. Those in the dosed group
also tended to die earlier. A life table analysis (method
which corrects for survival differences in groups) found
this difference to be significant (p < 0.05) (Table 6).
In the dosed group from day 23 to day 41 no tadpole
deaths occurred, and six of the seven frogs appeared.
On the next day (day 42) three tadpoles died but one
new frog was formed. From this time on, no new frogs
appeared. Tadpoles on day 51 (see Table 4) showed sta-
Table 6. Estimated Kaplan-Meier (K-M) probabilities for formation and rates of death of frogs in TCDD-contaminated water.
Dose level, % Cumulative K-M probabilities
ppb Days dosed No. P No. NFP No. DP NF DF
0 8 20 0 0 0 0
16 20 0 0 0 0
18 - - - 0 0
23 20 0 0 0 0
29 19b 0 0 0 0
30 19 0 0 0 0
31 - - - 0 0
38 17 2 0 10.5 0
41 - - - 10.5 0
42 16 1 0 15.8 0
44 15b 0 0 15.8 0
45 14b 0 1 15.8 5.9
48 - - - 15.8 5.9
51 13b 0 1 15.8 11.8
52 - - - 15.8 11.8
53 - - - 15.8 11.8
58 10 3 1 35.2 18.1
66 5c 1 1 43.3 25.5
0.1 8 20 0 0 0 0
16 20 0 0 0 0
18 l9b 0 0 0 0
23 18 1 0 5.3 0
29 - - - 5.3 0
30 16 2 0 15.8 0
31 16 0 3 15.8 15.8
38 13 3 0 31.6 15.8
41 13 0 1 31.6 21.1
42 gd 1 1 37.3 26.7
44 - - - 37.3 26.7
45 - - - 37.3 26.7
48 8 0 0 37.3 26.7
51 8 0 0 37.3 26.7
52 8 0 1 37.3 34.0
53 8 0 1 37.3 41.4
58 le 0 0 37.3 41.4
66 1 0 0 37.3 41.4
aT = Tadpole; NF = new frogs; DF = dead frogs.
b1 Tadpole dead.
c4 Tadpoles dead.
d3 Tadpoles dead.
e7 Tadpoles dead.
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tistically significant body size diminution from the con-
trol group, suggestive of TCDD toxic effects. Also 7
days later (day 58), seven ofeight tadpoles were dead.
The control group on day 58 had 10 live tadpoles as well
as three new frogs. By day 66, four tadpoles were dead
but one new frog was formed. The cause of the four
tadpole deaths at day 66 in the control group is not
known, but a limited number of frogs can be formed
while tadpoles are dying. The effect ofthe daily addition
of acetone was not separately studied.
Discussion
Most signs ofTCDD (and related compounds) toxicity
resemble signs seen in thyroid dysfunction, e.g., loss of
bodyweight and appetite, bradyeardia and tachyeardia,
alopecia and hirsutism, hyperkeratosis, altered levels
of triglycerides and cholesterol (2,7). The role of the
thyroid in mediating the toxicity of TCDD has been
considered (8). TCDD andrelatedcompounds havebeen
shown to deplete thyroxine (T4) in a dose-dependent
manner (8,9), suggesting perhaps more direct involve-
ment ofT4-binding proteins and receptors. The thyroid
hormones are water-insoluble molecules that require
specific binding proteins in the plasma and the cell cy-
tosol to enable them to gain access to nuclear receptors
(16). Thus, aplausible mechanismforTCDD and related
compound toxicity could be associated with their ability
to bind thyroid hormone receptors and function as po-
tent and persistent agonists or antagonists.
Common Molecular Reactivity Properties
of TCDD and T4
If TCDD is replacing T4 at the level of the nuclear
receptors, T4 must also possess molecular reactivity
characteristics in common with TCDD. TCDD is a rel-
atively planar and rigid structure which can present a
planar face and lateral halogens in interactions with
proteins. T4 is also conformationally rigid (12) because
ofthe steric constraints ofthe large iodine atoms in the
3,5positions and canalsopresentaplanarface, although
nonplanar in total structure, and lateral halogens in in-
teractions with proteins. Figure 3 shows the stereopair
superposition ofTCDD and T4. The relationship ofthe
two structures is primarily determined by the corre-
spondence of the lateral halogen substituents as pre-
dicted by the TCDD-prealbumin modeling studies (5)
and by a least squares fit ofthe important atoms (Table
1). In this arrangement, TCDD can best model T4 in
terms of overall molecular reactivity. In this modeling
exercise it is clear that the part (the planar face) ofthe
molecular structure of T4 that interacts with the Ah
receptor has to be the nonphenolic ring bearing the
alanine side chain (See Fig. 3 and Fig. 4, interaction
model, RnDxAh*). The planarface ofthe phenolic ring
is sterically inaccessible. Molecular size and shape are
not controlling factors in binding the Ah receptor (3).
A bettermodel is based on molecularpolarizability (dis-
persion interactions) and equilibrium separation dis-
tance between receptor and effector molecule. This is
consistent with a stacking or layering ofmolecules type
model as in charge-transfer complexation. The Ah re-
ceptor appears to bind T3 with about five to ten times
the affinity of T4 but binds TCDD with about 10 times
the affinity of T3 (17).
Formationofcharge-transfercomplexesinvolvingac-
cessible planar faces of these molecules is suggested.
Toxic structures related to TCDD are known (3) to form
charge transfercomplexes with donormolecules and we
haverecentlydemonstrated inpreliminarystudies (data
notshown)involvingNMR spectroscopicmeasurements
that complexes of this type are also formed with the
nonphenolic ring ofT4 and T3. Thus TCDD and active
hormones appear to have common molecular reactivity
properties with regard to their interaction with the Ah
receptor.
In recent studies of the interactions of compounds
related toTCDD with TBPA (5), amodelforthe nuclear
thyroid hormone receptor (4), we demonstrated using
computer graphics and competitive binding experi-
ments that dioxin type structures can be effective com-
petitive binding ligands for thyroxine-specific binding
sites inprealbuminandthatlateralchlorine substitution
isimportant in thisinteraction. These studies linked the
structure of thyroxine to TCDD and established yet
another common molecular reactivity property (lateral
halogens) ofthese molecules that is consistent with the
structure-toxicity relationship and the requirements of
planarity of structure and lateral halogenation in tox-
icity. Thus, both TCDD and T4 are conformationally
rigid structures which have accessible planar faces and
lateral halogens and have been shown to bind the same
protein models. These protein models require planar
structures and lateral halogenation for strong binding
and therefore have toxicological relevance.
FIGURE 3. Stereopair superposition ofTCDD and T4 in cooperative binding model (Rn Dx Ah*; see Fig. 4).
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Rn Dx Ah*
FIGURE 4. Simple mechanistic model for TCDD toxicity based on molecular reactivity properties.
Cooperative Protein Receptor Mechanism
Model for Toxicity
In our previous work (5), we proposed a new coop-
erative protein receptor mechanism for TCDD action
based on molecular structure and reactivity consider-
ations involving relevant protein interactions. We now
firther define this mechanism (see Fig. 4). In this model,
the Ah receptor can be viewed as a storage and trans-
locating protein for thyroid hormones which is in equi-
librium with the nuclear binding events and under certain
conditions can be found in both cytosolic and nuclear
compartments of the cell. T3 binds to nuclear binding
siteswithmarkedly higheraffinitythantocytosolic sites
(18), but the cytosol has greater binding capacity for T3
and presumably TCDD. The somewhat higher affinity
of T3 (as compared to T4) for the cytosolic sites may
serve to selectively displace T4 toward nuclear sites as
T3 accumulates from metabolism of T4. In contrast,
TCDD can apparently bind both the cytosolic and nu-
clear sites with high affinity and for TCDD the cytosolic
sites would be sites of loss with respect to the nuclear
sites. The equilibrium movement of these storage and
translocating proteins in and out ofthe nucleus can thus
be controlled by a concentration gradient determined
by available binding ligands and their affinities and pro-
tein binding capacity. The Ah receptor may upon trans-
location to the nucleus undergo a conformational change
Cytoplasm
Recycling
or
Resynthesis
Ah -
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(Ah*) which furtherstabilizes bindingofacharge-trans-
fer type. In this binding mode, the lateral chlorines in
TCDD are free to probe the DNA molecular surface for
a second receptor (Rn) which provides binding pockets
that closely match the structure and chemistry of the
lateralhalogens similartothosefoundinTBPAbinding.
In recognizing and binding these pockets the TCDD
molecule would probably assume anorientation like that
shown in Figure 3 (relative to T4). This would weaken
the overall dispersion interactions ofTCDD in the two
protein complex bringing it more in line with those of
T4. It is also quite likely that this cooperative binding
event is further stabilized by protein-protein
interactions.
The complex resulting from the cooperative binding
of these two proteins to TCDD and related structures
could activate the subsequent nuclear events leading to
a biological response. The cooperative binding event
introduces considerable structural specificity to the ac-
tivation process. IfTCDD is viewed as replacing T4 in
this process, the normal process may be regulated by
the intranuclear metabolic conversion ofT4 to T3 which
equilibrates in the direction of the cytosol sites to dis-
place more T4 for the nuclear sites to further initiate
the biological response. In contrast, TCDD can not be
controlled metabolically, i.e., by dehalogenation, and
therefore maintains the process inafullyactivated state.
Relationship of Mechanism Model to
Toxicological Findings
A unifying hypothesis of the mechanism of action of
TCDD should not only provide answers to specific tox-
icological problems but should provide a reasonable bi-
ological frame ofreference for the diversified effects of
TCDD and related compounds. Recent workers (19) have
shown that chemical thyroidectomy effectively protects
athyroid rats from the toxic effects (body weight loss
and mortality) ofTCDD whereas nonthyroidectomized-
euthyroid and thyroidectomized-T4-maintained-euthy-
roid rats were not protected. Our cooperative receptor
mechanism model predicts that it should be possible to
potentiate TCDD toxicity since the Ah receptor can
function as a site ofloss with respect to toxicity (3). We
have in fact shown that the thyroid hormones do bind
the Ah receptor (17) and do potentiate TCDD toxicity
as measured in the mouse teratogenicity system (20)
and in a bone marrow cell culture system (M. Luster,
unpublished observations). Thus the protection derived
from thyroidectomy can be possibly explained as a re-
duction in the potentiation of TCDD toxicity that nor-
mally operates in TCDD toxicity with unaltered levels
ofT3. However, potentiation would be expected to reach
a maximum at saturating levels (for the Ah receptor)
ofthyroid hormones.
The striking effects of TCDD on certain organ sys-
tems have suggested an endocrine basis, particularly
involving glucocorticoids, for its toxicity (7). Glucocor-
ticoids and thyroid hormones are known (21) to have
synergistic effects in cell systems in which the gluco-
corticoid effect appears to be controlled by thyroid hor-
mone; whereas glucocorticoids are not required for
thyroid hormone action, they enhance the effect. Con-
sistent with these observations is recent work (22) which
suggests that reproducible and stable association ofthe
occupied glucocorticoid receptor to its putative regu-
latory gene site may require the presence of occupied
thyroid hormone receptor which may be adjacent to the
glucocorticoid receptor binding site of the gene. Glu-
cocorticoids are also known (23) to induce changes at
the level of the nuclear thyroid hormone receptor site.
Guinea pigs made toxic with thyroxine show an in-
creased output of glucocorticoids (24). Glucocorticoids
can exert dramatic catabolic effects on lymphoid tissue
(25). One of the most striking and consistent effects
found in TCDD-treated animals is depletion oflymphoid
tissues (7), especially the thymus. Thus, varying levels
of glucocorticoids in TCDD toxicity may modulate the
thyroxine-like effects of TCDD at the level of nuclear
receptors.
In terms of the diversified effects of TCDD toxicity,
one would expect to find both hypo- and hyperthyroid
effects since TCDD does not have the amino acid prop-
erties ofT4 and, therefore, cannot be afull agonist. The
effects of thyroid hormones at the level of nuclear re-
ceptors appear to be primarily associated with their
halogenatedaromatichydrocarboncharacterandTCDD
is an agonist with respect to these effects. However,
the apparent role of thyroxine as a melanin precursor
can not be fulfilled by TCDD since it depends on the
amino acid properties ofthyroxine (26a). Therefore, in
TCDD toxicity there would be a lack of thyroxine for
this purpose because of its depletion in serum and tis-
sue. Abnormal skin, hair and nail proteins are all signs
of hypothyroidism (26b) which are also associated with
the toxicity of TCDD and related compounds (1).
Different toxicological endpoints may be mediated by
nuclear receptors in various thyroid hormone-respon-
sive organs in which thyroid hormone activity regulates
gene expression. Thyroid hormones and nuclearthyroid
hormone receptors have been previously implicated in
both normal (27) and tumor cell (28) proliferation. In-
creased protein synthesis and cell proliferation seen in
TCDD toxicity can be explained if TCDD acts as a po-
tent and persistent T4 agonist at the level of nuclear
receptors. Aheuristicmodelhasrecentlybeenproposed
(29)forthewastingsyndromeinTCDDtoxicityinwhich
TCDD treatment appears tolowerthelevelofregulated
body weight in the animal in a dose-dependent fashion.
Hypophagia serves as a secondary response to reduce
the animals weight to the lower regulation level deter-
minedbythe doseofTCDD administered. This setpoint
process could be controlled by the circulating levels of
thyroxine. A lethal dose of TCDD functioning as a T4
agonist may initiate this process at the level of tissue
receptors resulting in wasting, associated dehydration
and death before the lower weight regulation level is
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reached. Increased protein synthesis and cell prolifer-
ation as shown in the mechanism model (Fig. 4) could
be associated with tissue hyperplasia, but it is also pos-
sible that the end result of gene expression could give
rise to tissue atrophy and hypoplasia (depending on tis-
sue type) where new protein synthesis could generate
repressor factors.
Differences in species sensitivities to TCDD toxicity
(2) are most likely related to differences in nuclear thy-
roid hormone binding capacity and pharmacokinetic fac-
tors. For example, the guinea pig has about one-third
the nuclear thyroid hormone binding capacity ofthe rat
asestimatedfromserumT4levels (thisisalsosuggested
by preliminary studies involving Scatchard analysis of
the thyroxine nuclear receptor in liver) and is unable to
eliminate T4 efficiently as can the rat. Because oflower
saturation levels for the relevant receptors in addition
to the additive effects of TCDD and T4 in occupying
thesereceptors, theguineapigisaverysensitive animal
species to the toxic effects of TCDD. Consistent with
this hypothesis is the fact that guinea pig weight loss
was used as an early screen forcompounds with thyroid
hormone activity (30).
We feel that the molecular reactivity characteristics
(dispersion interactions involving the ring system and
lateral halogens) underlying our mechanistic model for
TCDD toxicity have a solid physicochemical basis and
can be used in a correlative approach for assessment of
activity beyond TCDD and related compounds, perhaps
even to structurally unrelated molecules. For example
the model predicts that certain highly chlorinated and
brominated diphenyl ethers and diphenylmethanes may
be toxic. Minimum requirements for toxicity would in-
clude two ortho halogens (for conformational rigidity),
two adjacent lateralhalogens (forbindingthe thyroxine
nuclear receptor, Rn) and a sufficient number of halo-
gens in one ring (opposite ring with lateral halogens) to
effect a good dispersion, stacking interaction (with the
Ah receptor). Also, implicit in our mechanistic model is
that the mechanism of TCDD toxicity at the level of
nuclear receptors shares common features with the
mechanism ofthyroid hormone action. Thus our model
should provide a new structural and reactivity frame-
work for studying the mechanism of thyroid hormone
action.
TCDD as a Thyroxine Agonist and
Relationship to Thyroid Hormone Action
Serum thyroid hormones appear to be in equilibrium
with tissue nuclear receptor sites (16). In this work, we
demonstrate a linear phase for depletion of T4 in rat
serum at relatively nonlethal doses ofTCDD which when
extrapolated to complete T4 depletion may provide an
estimation of the lethal dose in this rat species (- 50
,ug/kgbodyweight). Thisisundoubtedly associatedwith
the significant enhancement of hepatic uridine diphos-
phate glucuronyltransferase activity by TCDD in rats
previously demonstrated (31) which is near maximal 9
days after TCDD administration. It was further shown
at a TCDD dose of 25 ,ug/kg body weight that there is
faster clearance of added T4. Thus serum T4 depletion
is reflecting tissue T4 depletion. Even though the 125I-
T4 was given orally in this study, it is highly unlikely
that these results are due to significant differences in
absorption and distribution properties of added T4 be-
cause of the small mass (- 88 ng) of T4 involved. In
addition, previous workers (7), using labeled nutrients,
found no difference in the absorption and distribution
properties ofglucose, alanine oroleateinTCDD treated
animals versus controls.
Tissue T4 depletion may be correlated with replace-
ment of T4 by TCDD at the level of tissue receptors.
In preliminary experiments (data not shown) with rat
liver nuclei from rats receiving toxic doses of TCDD,
we find an increase in the number ofthe nuclear recep-
tors for thyroxine consistent with their modulation by
thyroid hormones (32). Alsoin preliminary experiments
(data not shown), TCDD and related compounds were
shown to compete for specific T4 binding sites in rat
liver nuclei in a manner consistent with the predictions
using TBPA as a model for the nuclear receptor (5).
These observations support the hypothesis that deple-
tion of tissue T4 is a reflection of its replacement by
TCDD at the level oftissue receptors in TCDD-treated
animals which may be the result ofreceptor occupancy
or alteration by TCDD molecules that persist in the
tissues. TCDD toxicity might therefore be in part re-
lated to the expression ofpotent and persistent thyroid
hormone activity initiated at the level of the nuclear
receptors.
Ifthis is true, we reasoned that it should be possible
to demonstrate at subtoxic doses thyroid hormone-like
activity for TCDD. We decided to use tadpole growth
and development as our model for this, in spite of the
fact that previous workers (33) had reported unsuc-
cessful experiments with tadpoles injected with TCDD.
Our experiments suggest an initial hyperactive phase
in which tadpole length (and growth rate) is increased
(detected only in the low dose group) followed by tox-
icity. Toxicity is expressed as a progressive diminution
in size eventually leading to death. Previous workers
(34,35) have shown that such rapid weight loss in tad-
poles is not related to a decrease in food consumption
but rather to a hyperactive state. This reproducible
result is in contrast to the no-effect result reported by
previous workers (33). Such an initial boost in metabolic
rate as seen in this work with TCDD has been well
documented for birds receiving various chlorinated hy-
drocarbon (36) insecticides. There is as yet no indication
that such an initial boost in metabolic rate occurs in
mammals, but we believe our results with the serum
T4 levels in TCDD treated guinea pigs provides an in-
dication of this. It is known (37) that UDP-glucuron-
yltransferase activity in guinea pigs is not induced on
TCDD treatment, in marked contrast to the rat. The
elevated serum levels we find in guinea pigs treated
with TCDD could be associated with aninitial metabolic
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boost followed by slow elimination of thyroxine by the
transferase system. Theeffect wasalready atmaximum
at 0.5 ,ug/kg body weight TCDD dose.
Previous workers (38) have studied the effects of
TCDD on oxidative phosphorylation rates in isolated
rat liver mitochondria. Although no statistically signif-
icant effects were seen, there was an indication of an
early boost in state 3 respiration which declined and
leveled off at later time points. Effects of TCDD on
oxidation rates in animals will probably be difficult to
demonstrate since any increase will be offset by de-
creases due to tissue wasting. We feel that these initial
boosts in metabolism are the result of increased syn-
thesis ofthyroxine derived from the competition ofthe
toxin with thyroxine for the serum hormone binding
proteins such as prealbumin or thyroxine binding glob-
ulin as proposed (6) for related compounds. However,
not all compounds which are capable of binding these
serum proteins and stimulating production ofthyroxine
are capable of binding the nuclear receptors and initi-
ating a response in tissues.
Thepreliminaryfindingofearlierand morerapid met-
amorphosis of tadpoles in the low dose group is con-
sistent with the proposal that TCDD can function as a
thyroid hormone agonist and interact directly with rel-
evant tissue receptors. The fact that some tadpoles in
this group never undergo metamorphosis and the frogs
that are formed die at a faster rate than controls sug-
gests that the dose-response curve for thyroid hormone
activity ofTCDD is steep and thattoxicityisthe expres-
sion ofpotent and persistent thyroid hormone activity.
Although we made no attempt in this study to measure
TCDD levels intadpole tissue, the persistence ofTCDD
in animal tissues is well documented (39). The dose-
response pattern seen for toxicity in this study along
with the very low concentrations ofTCDD required to
produce effects are consistent withthe potency and per-
sistence ofTCDD as a thyroxine agonist. TCDD is also
a potent embryotoxic agent in rats and mice (40) ex-
hibiting an extremely steep dose-response curve (L.
Birnbaum and J. Lamb, personal communication) con-
sistent with its effects on tadpole metamorphosis, a
somewhat analogous developmental process.
One would also expect, as in dioxin toxicity, that the
Ah receptor interaction may be a necessary but not
sufficient condition for hormone activity. Thyroid hor-
mone action may be modulated by a controlled passage
across nuclear membranes (41). Nuclear receptor affin-
ity for thyroid hormones and thyroid hormone analogs
correlate wellwiththe biological activities ofthese com-
pounds (26c). However, equal affinity of the nuclear
receptor for D and L forms of the hormones, for triio-
dothyroacetic acid (in spite oflesser biological activity),
for reverse triiodothyronine (reported to have little or
no biological activity) presents some problems in inter-
preting the nuclear receptor-binding data. In prelimi-
nary work using "'I-labeled thyroid hormones and
selected analogs in subcellular localization studies, we
find that nuclear localization varies in a manner con-
sistentwithknownbiologicalpotencies ofthehormones,
in spite of equal affinity of some of the hormones for
isolated nuclear binding sites. The possibility that hor-
monal activity is modulated by the Ah receptor is con-
sistent with the observations that T3 binds the Ah
receptor with about five to ten times the affinity of T4
(17), potentiates the toxicity ofTCDD five times better
than T4 (20) and is three to five times more active than
T4 as a hormone (42a).
Removal of the ether oxygen to form the linear bi-
phenyl analog ofthyroxine is a particularly interesting
test model for our mechanism. This analog would be
expected to be inactive forthe same reasons that ortho-
substituted polychlorinated biphenyls are nontoxic (43),
i.e., both would have weak interactions with the Ah
receptor, andthuswould havelimited accesstorelevant
nuclear binding sites. In limited tests, the biphenyl an-
alogs ofthethyroid hormoneswere showntobe inactive
(42b). Other areas ofnew insight into the mechanism of
thyroid hormone action predicted by our model for which
experimental support already exists include the multi-
ple component nature (44) ofthe nuclearbinding events
and that T4 has intrinsic hormonal activity and is not
merely the prohormone ofT3 (45). Since T3 can poten-
tiate the toxic effects of TCDD and since TCDD can
replace T4 in biological systems, it is possible that T3
is a natural potentiator of T4 activity. In preliminary
studies (M. Luster, unpublished observations), we have
in fact qualitatively reproduced TCDD toxicitybyusing
combinations of T3 and T4 while either hormone alone
was ineffective. This result suggests that combinations
ofT3 and T4 are much more effective in producing thy-
roid hormone activity than either hormone alone. The
fact that T4 is selectively depleted in TCDD toxicity is
also consistent with it being the controlling form ofthe
hormone.
Finally, this work suggests a logical role for reverse
T3 (rT3) in thyroid hormone action as a natural intran-
uclear antagonist ofT4. Reverse T3 would be expected
to bind weakly to theAh receptor and have only limited
accesstonuclearbindingsitesbecauseofconformational
flexibility (12) and the presence ofonly one iodine atom
in the nonphenolic ring. This is supported by prelimi-
nary findings (data not shown) that reverse T3 shows
little accumulation in nuclear fractions in rat liver cells.
Its presence in the nucleus is probably controlled by
nuclear metabolism of T4. The intranuclear formation
ofrT3 is also consistent with the observations that rT3
binds to solubilized nuclear receptors (46) forthyroxine
but fails to bind when intact nuclei are used (47). There-
fore, rT3 formed in the nucleus can bind the nuclear T4
receptors (although with a lower affinity than T3 or T4)
but can not simultaneously bind both the nuclear re-
ceptor and the cytosolic receptor to effect a biological
response as illustrated in Figure 4 for TCDD. This model
for antagonism differs from the one for potentiation
where the potentiating chemical has a preference for
the cytosolic receptors and increases the population of
active molecules available to nuclear receptors. In pre-
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liminary work, we have demonstrated antagonism of
TCDD toxicity by structures related to dioxin as well
as thyroxine in a bone marrow cell culture system. These
antagonists are capable ofbinding either the Ah recep-
tor or the thyroxine nuclear receptor alone but can not
simultaneously bind bothreceptors with different struc-
tural parts (as shown for TCDD in Fig. 4). Thus this
receptor model is also pointing to new directions in the
search forthe highly elusive competitive inhibitorofthe
thyroid hormones (antithyroid drugs).
Conclusions
The resistance to metabolism and persistence ofTCDD
in animal tissue are well documented (39). Because of
this persistence in tissue and common molecular reac-
tivity properties, TCDD can replace thyroxine in the
tissues at the level of nuclear receptors and act as a
highly active but metabolically uncontrollable thyroid
hormone analog. The most serious end result is a run-
away catabolism (probably to meet an increased re-
quirement for metabolic energy) resulting in a wasting
syndrome and associated dehydration ultimately lead-
ing to death (at lethal doses) which resembles in many
ways the toxicity produced by thyroxine itself(25). The
thyroid gland would be isolated in a hyperactive state
(8), since it is reacting to what it detects is a reduction
ofthyroxine (local T4 metabolism is primary source of
pituitary T3).
Effects on tadpole growth and development provile
strong supporting evidence that the mechanism ofdioxin
toxicity is the mechanism of thyroid hormone action.
This is also supported by preliminary studies with the
nuclear receptor for thyroxine. TCDD may be a very
unusual thyroid hormone analog in that it is capable of
binding both T3 and T4 receptors with high affinity. In
terms ofthyroid hormone activity, the TCDD molecule
accomplishes in one structure what normally requires
two different structures (T3 and T4) working in coop-
eration through potentiation and metabolic regulation
to maintain the appropriate levels of nuclear T4. The
environmental health concern over TCDD and related
compoundswouldbeclearlyjustified ifthesecompounds
can function as potent andpersistent thyroxine agonists
and produce a number ofhealth effects associated with
hypo- and hyperthyroidism.
A molecular mechanism is proposed involving a two
protein-receptor model in which the planar aromatic
system controls the initial receptor binding in cytosol
and halogen substituents control subsequent nuclear
events. Although a complete delineation of the mech-
anism at the molecular level has not been done, the
proposed mechanistic model based on molecular reac-
tivity characteristics has brought immediate insight to
anunderstanding ofthe diversified effects ofTCDD and
related compound toxicity and certain thyroid hormone
action. In addition, the mechanistic model also permits
predictions to be made with regard to the toxicity and
thyroid hormone activity (agonists, antagonists, etc.) of
untested compounds. In fact, the two separate lines of
research are in many ways mutually parallel and
reinforcing.
Finally, the work has suggested ageneral mechanism
for hormone action based on metabolically regulated
differential and cooperative receptor binding events in
cellular compartments which can explain agonism, an-
tagonism and potentiation within the framework of re-
ceptor occupancy theory (48). In this general mechanism,
a metabolite (like T3) ofthe active hormone (T4) would
bind cytosol receptors with somewhat greater affinity
than the active hormone itself. The metabolite can dis-
place the active hormone from the cytosolic receptor
freeingthe hormone forbindingto nuclearsites onchro-
matin to which it binds with greater affinity than the
metabolite. This push to nuclear binding of the active
hormone is enhanced as the concentration ofmetabolite
increases by intranuclear conversion ofthe hormone to
the metabolite. The active hormone is maintained at a
fairly constant level in body fluids and tissues by the
appropriate organ systems (pituitary/thyroid axis). The
molecular reactivity properties of the hormone can be
viewed as a steering mechanism for bringing together
the two proteins on chromatin and initiating the biolog-
ical response. Once the hormone has accomplished this
task, it may be metabolized with a different biological
half-life thanthatoftheactivated proteincomplexitself.
This process requires binding to two different pro-
teins by two different chemical mechanisms in order to
initiate a response, thereby establishing structural
specificity. Thenecessaryconcentration gradienttoreg-
ulate the process is established by differential binding
of the active hormone and its metabolite to the two
proteins. Thiswouldhaveitsanalogyinsteroidhormone
action where testosterone is known (49) to be an active
hormoneandisalsoconvertedintodihydrotestosterone,
which is twice as potent possibly because it is a better
potentiator oftestosterone activity than is testesterone
itself. This points to new directions in studies of hor-
mone receptor biochemistry and drug design and sug-
gests that toxicity studies involving chemical
combinations will produce interesting results.
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